TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in mean 24-hour average general pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in parenteral support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in phosphate binder tablet usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of successful IVF treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion of the cervical interbody cage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of vertebral fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in bioequivalence (AUC-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in therapeutic equivalence (UPDRS part III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Freedom From Migraine Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective remission rate (ORR)
Endpoint domain: Physiological/clinical
Primary endpoint: failure of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal cuff dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day HF re-admission
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of FRAGIL-IT tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of DELPhI in subjects at risk for stroke and dementia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Anterior Knee Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fasting cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With a Decrease of ≥20% in Forced Expiratory Value in One Second (FEV1) Percent (%) Predicted From Pre-dose to 30-minute Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIV plasma viral load < 50 cp/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Static Physician's Global Assessment (sPGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged pain after arthroplastic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to cow's milk protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Pain Over the Last 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of bacterial biofilm on orthopaedic implants
Endpoint domain: Adverse events/effects
Primary endpoint: short interval intracortical inhibition (SICI) measured by threshold tracking TMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short interval intracortical inhibition (SICI) measured by conventional TMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of GABA and glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete renal response (CR) at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oculocardiac reflex occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reasons for switching to Betaferon
Endpoint domain: Adverse events/effects
Primary endpoint: Factors predictive of non-adherence to disease modifying drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage From Baseline in Success of Penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Success of Erection Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of Participants With Paced Successfully by Programmed Extrastimulation (PES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High Rate (Burst) Stimulating Successful Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success Rate of Sinus Node Recovery Time (SNRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve (AUC) for Serum C-peptide Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Regression of Metastatic Renal Cell Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value (PPV) on a Per-patient Basis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) on a Per-region Basis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite clearance at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Border delineation of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of internal morphology of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast enhancement of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of selected SHS constituents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and efficacy of sirolimus, tacrolimus and methotrexate regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects reaching or maintaining the risk target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Donor T-cell chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Facial wrinkle scale change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harvest of at least 2 x10^6 CD34+/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fractional exhaled nitric oxide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic performance of FFRB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 7-day Prevalence of Abstinence From Cigarette Smoking at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7 Day Prevalence of Abstinence From Cigarette Smoking at 24 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wound assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Arterial blood concentration of isoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Degree of Postoperative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree and Improvement of Ocular Surface Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal artery calibre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment-Emergence Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically diagnosed DVT and/or PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Volumetric measurement of cranial defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ultrasound derived bloodflow in superior mesenteric artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neural responses to change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with death
Endpoint domain: Mortality/survival
Primary endpoint: Discrimination thresholds for formant frequency differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) for Anti-diphtheria and Anti-tetanus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) for Anti-pertussis Toxoid, Anti-filamentous Haemagglutinin and Anti-pertactin Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Anti-poliovirus Types 1, 2 and 3 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Booster Response Against Diphtheria and Tetanus Toxoid Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Lower Extremity Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delta heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FENO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Antibodies Against HPV-16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attendance at the free orientation session for Cardiac Rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mentalization impairments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Uterine bleeding control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the SF-6D Measure Health Utility Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: salivary secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary buffering capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of EA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7 days AKI occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Onset time of brachial plexus blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative hemogram values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postvoiding residues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of clinical illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to alleviation of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment rate
Endpoint domain: Mortality/survival
Primary endpoint: Risk of graft-vs-host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of black spots in diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Tolerated Doses (MTDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients without major toxicities or morbidities
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic catheter related sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Significant catheter culture >=103 cfu/ml
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Newly Diagnosed Basal Cell Carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Size Reduction (Objective Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vascular flow of the carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area under the concentration versus time curve (AUC) of rivaroxaban in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) of rivaroxaban in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Freedom at 2 Hours After Initial Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of the Most Bothersome Migraine-Associated Symptom at 2-Hours After Initial Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative survival rates for the implants
Endpoint domain: Mortality/survival
Primary endpoint: Change in BOLD Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Catheter-related thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Catheter-Related Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Dislodgment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of exudation
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative emesis
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the amount of collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plasma Concentration of Ivermectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Observed Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of runny nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Venous Thromboembolism (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Geriatric Depression Scale (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of migraine in rosacea cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of rosacea in migraine cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gait measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients requiring vascular imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, or thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin drop >3g/dl with over bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HPV screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients with 20% improvement response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term presence of knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Polyp resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Injection Site Adverse Experiences (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission Rates in Patients With MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improving Social and Occupational Functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adverse Antidepressant Treatment Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum distance between planned and achieved trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone erosion score on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Development of peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in baseline area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vertical distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the rapid antigen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the rapid antigen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine artery doppler changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Biodex results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of Analgesia as Judged by Age-adjusted Pain Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Fentanyl Administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of colonisation with SsK12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response Rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous Rehydration Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of referral to surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in proportion of children meeting physical activity policy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Star Excursion Balance Test (SEBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Post-Concussion Assessment Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal ventilatory aerobic endurance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal lactate aerobic endurance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with stroke complications
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking cessation psychological dependence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve (AUC) of Idasanutlin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Idasanutlin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of decitabine based on incidence of DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Caspase-8 expression in bone marrow or tumor biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CTP-543 exposure in plasma under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes